Actually, inhibition of the BRAFV600E/MEK/ERK axis in thyroid cancer cells also results in reactivation of a variety of RTKs such as HER2/HER3 [69, 70], platelet-derived growth factor receptor-beta (PDGFRβ) [69], and EGFR [71]. Here, ERBB3 is linked to thyroid cancer.